AZN•benzinga•
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
Summary
AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion deal includes an initial payment of $425 million, with additional contingent consideration.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga